Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-450 in moderate to severe hidradenitis suppurativa
NCT05216224Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zunsemetinib in hidradenitis suppurativa (HS), sponsored by Aclaris Therapeutics, Inc.. Started Dec 2021; status: completed.
02
Drugs
zunsemetinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05216224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216224.